Lv3
390 积分 2022-11-14 加入
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
13天前
已完结
Advances in PSMA-Targeted Radionuclide Therapeutics
2个月前
已完结
Resolute Progress Down a Long and Winding Road Leads to the Promised Land of Prostate-Specific Membrane Antigen–Based Therapies for Prostate Cancer
2个月前
已完结
Small molecules, big impact: 20 years of targeted therapy in oncology
2个月前
已完结
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu-PSMA-617
2个月前
已完结
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
2个月前
已关闭
Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS
2个月前
已关闭
Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to 177Lu-PSMA-617: A Retrospective Multicenter Cohort Study
2个月前
已完结
Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS
2个月前
已关闭
Lower Testosterone level and metastases-free survival in nmCRPC patients treated with novel antiandrogens: A post-hoc analysis of SPARTAN and ARAMIS
2个月前
已关闭
皖公网安备34019202002308
